Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

/p>

per common share:

Earnings available

to common shareholders

before cumulative

effect of a change

in accounting

principle $0.69 $0.87

Cumulative effect

of a change in

accounting principle,

net of tax 0.02 -

Diluted earnings

per common share $0.71 $0.87

Average common

shares outstanding

-diluted 1,491 1,491

SCHERING-PLOUGH CORPORATION

Reconciliation from Reported Net (Loss)/Income Available to Common Shareholders and Reported Diluted (Loss)/Earnings Per Common Share to As Reconciled Amounts for Net (Loss)/Income

Available to Common Shareholders and Diluted (Loss)/Earnings per Common Share (unaudited)

"As Reconciled" amounts related to Net (loss)/income available to common shareholders and diluted (loss)/earnings per common share reflect the following adjustments:

(Amounts in Millions)

Fourth Quarter Twelve Months

2007 2006 2007 2006

Purchase accounting

adjustments:

Amortization of intangibles

in connection with the

acquisition of Organon

BioSciences (a) $65 $- $65 $-

Depreciation related to

the fair value adjustment

of fixed assets related

to the acquisition of

Organon BioSciences (a) 3 - 3 -

Charge related to the

fair value adjustment

to inventory related

to the acquisition of

Organon BioSciences (a) 258 - 258 -

Acquired IPR&D related

to the acquisition of

Organon BioScience
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...NA, Austria, November 19 AFFiRiS A...e product candidate at an unexpectedly early,stage...nned to enter into,Phase II clinical trial early i...ollows the completion of two Phase I trials with t... fast decision on the first interim,analysis of th...
(Date:11/18/2009)...onal Institute of Standards and Technology (NIST) ...method for detecting and measuring elusive hazards...e spoilage in food or pesticides distributed in so...sensitive than conventional techniques for detecti...water molecules, having distinct electrically posi...
(Date:11/18/2009)...agine a polka-dotted postage stamp that can sniff ...nging colors. , As reported in the Sept. 13 issu...ck and his team at the University of Illinois have...ction of toxic industrial chemicals (TICs) that is...izing odors. This sensor array could be useful in...
(Date:11/18/2009)...alif., Nov. 18 Sangamo B...that data from the University of Pennsylvania inve...,s zinc finger nuclease (ZFN) based product, SB-72...ly disclosed on the internet. ,, Data were pres...nsylvania School of Medicine from a single subject...
Breaking Biology Technology:AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Prototype NIST method detects and measures elusive hazards 2Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2
...will,grace the faculty of the "Pharma & Biotech Co...ence in two weeks in New Jersey. The conference is... Analysis, and Market,Forecasting executives; 200 ...-2 to attend the meeting. Competition has never be...or competitor moves in crowded,therapeutic classes...
... Measure Cardiac Output During Cardiop...ember 19 Cheetah Medical Inc.,developers of the C...me,cardiac output monitoring, announced at HFSA th...fficiency in heart failure are related to peak,exe...rd University and the VA Palo,Alto Health Care Sys...
...Ventures, Kleiner Perkins Caufie...of Technology Pioneer at Forefront of Developing N...EMERYVILLE, Calif., Sept. 19 Amyris Biotechnologi...ydrocarbon biofuels, today,announced that it close...nding. Duff Ackerman & Goodrich Ventures (DAG Vent...
Other Biology Technology:New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting 2Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting 3Amyris Biotechnologies Announces $70 Million Series B Round 2
(Date:11/22/2009)...renatally to tobacco smoke and during childhood to...rding to research done at Cincinnati Children,s Ho...t up to 35 percent of ADHD cases in children betwe...ating both of these environmental exposures. This ...Tobacco and lead exposure each have their own impo...
(Date:11/22/2009)...09 Agios Pharmaceuticals today announced that its...that the mutated IDH1 gene has a novel enzyme acti...ogene. This breakthrough discovery shows that the ...oxyglutarate (2HG), which may contribute to the fo...most common type of brain cancers. This discovery ...
(Date:11/20/2009)...d studies about the health benefits of having a li...r level, where amino acids known as cysteines are ...en paired up with other cysteines. , Now, resear...lleagues in Belgium, have discovered a new antioxi...search appears in the Nov. 20 issue of the journal...
Breaking Biology News(10 mins):Exposure to lead, tobacco smoke raises risk of ADHD 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4Saving the single cysteine: New antioxidant system found 2Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010 12805 1Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010 12805 2Groups to Congress 3A Dont Sacrifice Patient Safety to Lower Health Costs 50184 1Groups to Congress 3A Dont Sacrifice Patient Safety to Lower Health Costs 50184 2Smoking May Trigger Brain Damage 50182 1Smoking May Trigger Brain Damage 50182 2
...esearch suggests that stress may activate immune c...disease. The related report by Joachim et al., "S...in Skews Dendritic Cells towards Maturation and Mi...ppears in the November issue of The American Jour...l of defense to infection, serving not only as a p...
...t to guide their nest-mates to good food sources, ...y of London. , For any animal, finding food on it...l animals such as bees reduce these problems by in...iting, them to the search. , Honeybees use their ...irection of a food source. But bumblebees can,t co...
...bies in Germany are born with alcohol-related defe...k alcohol regularly during the pregnancy. The cons...t into adulthood. The various forms of fetal alcoh...icians Hans-Ludwig Spohr and Hans-Christoph Steinh...International ( Dtsch Arztebl Int 2008; 105[41]:...
Other Biology News:Stress may make you itch 2
Rabbit Anti-Human MMP-13 Collagenase-3, amino terminal end of active enzyme, Antibody, Unconjugated from CEDARLANE Laboratories Limited
Mouse Anti-BCAR1 Monoclonal Antibody, Unconjugated, Clone SPM302 from Abcam
Anti-Phosphotyrosine IgG Monoclonal Antibody, Alkaline Phosphatase Conjugated, Clone AD548 from Assay Designs/Stressgen Bioreagents
Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam
Biology Products: